Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?
Authors
Keywords
-
Journal
BIODRUGS
Volume 37, Issue 6, Pages 855-871
Publisher
Springer Science and Business Media LLC
Online
2023-10-13
DOI
10.1007/s40259-023-00631-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal Antibodies
- (2022) Elena Guillen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective
- (2021) Pekka Kurki et al. DRUGS
- The Path Towards a Tailored Clinical Biosimilar Development
- (2020) Martin Schiestl et al. BIODRUGS
- Differential influence on antibody dependent cellular phagocytosis by different glycoforms on therapeutic Monoclonal antibodies
- (2020) Scott Kuhns et al. JOURNAL OF BIOTECHNOLOGY
- Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial
- (2020) Marie-Christine Bielsky et al. DRUG DISCOVERY TODAY
- Evolution of the EU Biosimilar Framework: Past and Future
- (2019) Elena Wolff-Holz et al. BIODRUGS
- An Efficient Development Paradigm for Biosimilars
- (2019) Christopher J. Webster et al. BIODRUGS
- Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars
- (2018) Kristof Vandekerckhove et al. AAPS Journal
- Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
- (2017) Seokkyun Kim et al. mAbs
- Do cancer drugs improve survival or quality of life?
- (2017) Vinay Prasad BMJ-British Medical Journal
- Do cancer drugs improve survival or quality of life?
- (2017) Vinay Prasad BMJ-British Medical Journal
- The Continuum of Comparability Extends to Biosimilarity: How Much Is Enough and What Clinical Data Are Necessary?
- (2013) M McCamish et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Acceptable changes in quality attributes of glycosylated biopharmaceuticals
- (2011) Martin Schiestl et al. NATURE BIOTECHNOLOGY
- Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
- (2010) P. P. Tak et al. ANNALS OF THE RHEUMATIC DISEASES
- Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion
- (2010) Edward M. Vital et al. ARTHRITIS AND RHEUMATISM
- The clinical application of monoclonal antibodies in chronic lymphocytic leukemia
- (2010) S. M. Jaglowski et al. BLOOD
- Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
- (2010) A. Rubbert-Roth et al. RHEUMATOLOGY
- Resistance to Trastuzumab in Breast Cancer
- (2009) P. R. Pohlmann et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now